These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36908770)

  • 21. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
    Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
    Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.
    Shima M; Amano K; Ogawa Y; Yoneyama K; Ozaki R; Kobayashi R; Sakaida E; Saito M; Okamura T; Ito T; Hattori N; Higasa S; Suzuki N; Seki Y; Nogami K
    J Thromb Haemost; 2023 Mar; 21(3):534-545. PubMed ID: 36696195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste.
    D'Albini L; Dorholt M; Gallucci L
    J Manag Care Spec Pharm; 2023 Jan; 29(1):47-57. PubMed ID: 36580124
    [No Abstract]   [Full Text] [Related]  

  • 24. Safety and efficacy of long-term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single-arm study (STASEY).
    Jiménez-Yuste V; Peyvandi F; Klamroth R; Castaman G; Shanmukhaiah C; Rangarajan S; García Chavez J; Martinez R; Kenet G; Alzahrani H; Robson S; Schmitt C; Kiialainen A; Meier O; Ozelo M
    Res Pract Thromb Haemost; 2022 Nov; 6(8):e12837. PubMed ID: 36397934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence.
    Linari S; Castaman G
    Ther Clin Risk Manag; 2020; 16():461-469. PubMed ID: 32547043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials.
    Jiménez-Yuste V; Oldenburg J; Tzeng E; Lim E; Sanabria F; Mahlangu J
    Res Pract Thromb Haemost; 2024 Mar; 8(3):102405. PubMed ID: 38783987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.
    Kiialainen A; Niggli M; Kempton CL; Castaman G; Chang T; Paz-Priel I; Adamkewicz JI; Levy GG
    Haemophilia; 2022 Nov; 28(6):1033-1043. PubMed ID: 35905294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
    Skinner MW; Négrier C; Paz-Priel I; Chebon S; Jiménez-Yuste V; Callaghan MU; Lehle M; Niggli M; Mahlangu J; Shapiro A; Shima M; Campinha-Bacote A; Levy GG; Oldenburg J; von Mackensen S; Pipe SW
    Haemophilia; 2021 Sep; 27(5):854-865. PubMed ID: 34171159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen.
    Bukkems LH; Fischer K; Kremer-Hovinga I; Donners AAM; Fijnvandraat K; Schutgens REG; Cnossen MH; Mathôt RAA
    Thromb Haemost; 2022 Feb; 122(2):208-215. PubMed ID: 33946119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single-center experience in Bangladesh.
    Tory SS; Ghosh S; Nazneen H; Farhad N; Islam S; Hasan MJ; Biswas AR
    EJHaem; 2024 Feb; 5(1):39-46. PubMed ID: 38406515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab.
    Levy-Mendelovich S; Brutman-Barazani T; Budnik I; Avishai E; Barg AA; Levy T; Misgav M; Livnat T; Kenet G
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A.
    Donners A; van der Zwet K; Egberts ACG; Fijnvandraat K; Mathôt R; Kruis I; Cnossen MH; Schutgens R; Urbanus RT; Fischer K
    BMJ Open; 2023 Jun; 13(6):e072363. PubMed ID: 37369395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea.
    Lee H; Cho H; Han JW; Kim AY; Park S; Lee M; Cho S; Baik D; Kang HY
    Haemophilia; 2021 Jan; 27(1):e12-e21. PubMed ID: 32894895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China.
    Liu G; Huang K; Li G; Zhen Y; Li Z; Chen Z; Wu R
    Front Pediatr; 2022; 10():992267. PubMed ID: 36340724
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A.
    Sun SX; Frick A; Balasa V; Roberts JC
    Expert Rev Hematol; 2022 Oct; 15(10):943-950. PubMed ID: 36000620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetic Analysis and Exploratory Exposure-Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A.
    Retout S; Schmitt C; Petry C; Mercier F; Frey N
    Clin Pharmacokinet; 2020 Dec; 59(12):1611-1625. PubMed ID: 32504271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A.
    Shima M; Nagao A; Taki M; Matsushita T; Oshida K; Amano K; Nagami S; Okada N; Maisawa S; Nogami K
    Haemophilia; 2021 Jan; 27(1):81-89. PubMed ID: 33236410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A.
    Schmitt C; Mancuso ME; Chang T; Podolak-Dawidziak M; Petry C; Sidonio R; Yoneyama K; Key NS; Niggli M; Lehle M; Peyvandi F; Oldenburg J
    Haemophilia; 2023 Jan; 29(1):90-99. PubMed ID: 36271487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis.
    Garcia J; Hammer MR; Zia A
    Res Pract Thromb Haemost; 2023 Nov; 7(8):102238. PubMed ID: 38053983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review.
    Donners AAMT; Rademaker CMA; Bevers LAH; Huitema ADR; Schutgens REG; Egberts TCG; Fischer K
    Clin Pharmacokinet; 2021 Nov; 60(11):1395-1406. PubMed ID: 34389928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.